Review clinical trials related to AIHA - Cold Autoimmune Hemolytic Anemia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
Active autoimmune cytopenia [+3]
Previous treatment with a BCMA-targeted therapy [+3]
This is a multicenter, open-label, single-arm Phase I clinical trial to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection treatment in autoimmune hemolytic anemia that has failed at least three lines of treatment.
Age range: 18-75 years (including 18 and 75 years), regardless of gender. [+1]
Previously diagnosed proliferative tumors of the lymphatic system; [+22]
Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The objectives of this study are to investigate the incidence and risk factors of autoimmune hemolytic anemia (AIHA) and to analyze the treatment effectiveness, patient prognosis and healthcare costs in China. 1. Analyze the demographic and clinical characteristics of patients with AIHA, including sex, age, disease severity, and other relevant factors. 2. Examine disease features of AIHA patients, such as biochemical and hematological indicators 3. Assess treatment patterns and real-world effectiveness in AIHA patients. 4. Evaluate clinical outcomes, including hematologic response, relapse, and mortality 5. Investigate long-term prognosis, including post-discontinuation outcomes and health-related quality of life.
Subjects diagnosed with AIHA. [+2]
Subject unlikely to be available for long-term follow-up for any reason (e.g., i... [+2]
To evaluate the efficacy and safety of ipecopam in the treatment of refractory/relapsed AIHA.
Voluntarily signed an informed consent form (ICF); [+14]
Presence of secondary AIHA outside the inclusion criteria; [+16]